var path='https://www.tickertech.net'; function heading(heading) { document.write('
'+heading+' |
'+ ''+ ' |
'); } function hiLite(imgDocID,imgObjName) { document.images[imgDocID].src = eval(imgObjName + ".src"); } function showStatus(toshow) { window.status = toshow; } function checkChoose() { if (document.choose.ticker.value == "") { alert("Please enter symbols before clicking the go button"); return false; } else return true; } function popJT(url,name){ var xwid = screen.width; xwid = xwid - 10; javaticker = window.open(url,name,'width='+xwid+',height=100,resizable=yes,scrollbars=no,toolbar=no,location=no,directories=no,status=yes,menubar=no'); javaticker.opener.name="opener"; //javaticker.moveTo(0,30); } var allow = 0; var ref = ""+location; if ((ref.indexOf("cryptocurrencieschannel.com") > 0) || (ref.indexOf("cefchannel.com") > 0) || (ref.indexOf("bdcinvestor.com") > 0) || (ref.indexOf("tickertech.com") > 0) || (ref.indexOf("xxxx:") > 0) || (ref.indexOf("javascript:") > 0) || (ref.indexOf("filseclab.com") > 0) || (ref.indexOf("msnscache.com") > 0) || (ref.indexOf("toolbar.google.com") > 0) || (ref.indexOf("etfchannel.com") > 0) || (ref.indexOf("marketnewsvideo.com") > 0) || (ref.indexOf("news.google.com") > 0) || (ref.indexOf("dividendchannel.com") > 0) || (ref.indexOf("www.google.com") > 0) || (ref.indexOf("energystockchannel.com") > 0) || (ref.indexOf("metalschannel.com") > 0) || (ref.indexOf("portfoliochannel.com") > 0) || (ref.indexOf("canadastockchannel.com") > 0) || (ref.indexOf("theonlineinvestor.com") > 0) || (ref.indexOf("investhelp.com") > 0) || (ref.indexOf("preferredstockchannel.com") > 0) || (ref.indexOf("stockoptionschannel.com") > 0) || (ref.indexOf("holdingschannel.com") > 0) || (ref.indexOf("tickertech.net") > 0) || (ref.indexOf("historicalstockprice.com") > 0) || (ref.indexOf("splithistory.com") > 0) || (ref.indexOf("stocksplithistory.com") > 0) || (ref.indexOf("google.c") > 0) || (ref.indexOf("208.71.46.190") > 0) || (ref.indexOf("search.yahoo") > 0) || (ref.indexOf("sharesoutstandinghistory.com") > 0) || (ref.indexOf("marketcaphistory.com") > 0) || (ref.indexOf("ytdreturn.com") > 0) || (ref.indexOf("averageannualreturn.com") > 0) || (ref.indexOf("redinews.com") > 0) || (ref.indexOf("technicalanalysischannel.com") > 0) || (ref.indexOf("stockdma.com") > 0) || (ref.indexOf("stockrsi.com") > 0) || (ref.indexOf("stockmacd.com") > 0) || (ref.indexOf("topdividends.com") > 0) || (ref.indexOf("monthlydividendpayingstocks.com") > 0) || (ref.indexOf("nextearningsdate.com") > 0) || (ref.indexOf("pastearnings.com") > 0) || (ref.indexOf("historicalperatio.com") > 0) || (ref.indexOf("historicalearnings.com") > 0) || (ref.indexOf("webcache.googleusercontent.com") > 0)) { allow = 1; } function ShowTTIPage() { if (allow) { document.write('\n'); } if (allow) { document.write('
\n'); } if (allow) { document.write('4/26 - 4:13 PM \; \; | \n'); } if (allow) { document.write('ALPINE IMMUNE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick &\; Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Alpine Immune Sciences, Inc. - ALPN | \n'); } if (allow) { document.write('
4/23 - 1:00 AM \; \; | \n'); } if (allow) { document.write('VERTEX AND TREEFROG THERAPEUTICS ANNOUNCE LICENSING AGREEMENT AND COLLABORATION TO OPTIMIZE PRODUCTION OF VERTEX\'S CELL THERAPIES FOR TYPE 1 DIABETES | \n'); } if (allow) { document.write('
4/18 - 8:00 AM \; \; | \n'); } if (allow) { document.write('Vertex Announces Advancements of Suzetrigine (VX-548) in Acute and Neuropathic Pain | \n'); } if (allow) { document.write('
4/12 - 5:17 PM \; \; | \n'); } if (allow) { document.write('ALPINE IMMUNE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick &\; Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Alpine Immune Sciences, Inc. - ALPN | \n'); } if (allow) { document.write('
4/10 - 4:01 PM \; \; | \n'); } if (allow) { document.write('Vertex Enters Into Agreement to Acquire Alpine Immune Sciences | \n'); } if (allow) { document.write('
4/10 - 4:01 PM \; \; | \n'); } if (allow) { document.write('Vertex Enters Into Agreement to Acquire Alpine Immune Sciences | \n'); } if (allow) { document.write('
4/9 - 4:05 PM \; \; | \n'); } if (allow) { document.write('Vertex to Announce First Quarter 2024 Financial Results on May 6 | \n'); } if (allow) { document.write('
4/1 - 11:01 AM \; \; | \n'); } if (allow) { document.write('Vertex Announces New Drug Submission for Exagamglogene Autotemcel (exa-cel) Has Been Accepted for Priority Review by Health Canada for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia | \n'); } if (allow) { document.write('
4/1 - 8:00 AM \; \; | \n'); } if (allow) { document.write('Vertex Advances Inaxaplin (VX-147) into Phase 3 Portion of Adaptive Phase 2/3 Clinical Trial for the Treatment of APOL1-Mediated Kidney Disease | \n'); } if (allow) { document.write('
3/21 - 8:00 AM \; \; | \n'); } if (allow) { document.write('Vertex Announces FDA Clearance of Investigational New Drug Application for VX-407 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) | \n'); } if (allow) { document.write('
2/20 - 4:05 PM \; \; | \n'); } if (allow) { document.write('Vertex to Participate in Upcoming Investor Conferences | \n'); } if (allow) { document.write('
2/13 - 1:59 AM \; \; | \n'); } if (allow) { document.write('European Commission Approves First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™\; (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia | \n'); } if (allow) { document.write('
2/5 - 4:07 PM \; \; | \n'); } if (allow) { document.write('Vertex Reports Fourth Quarter and Full Year 2023 Financial Results | \n'); } if (allow) { document.write('
2/5 - 4:01 PM \; \; | \n'); } if (allow) { document.write('Vertex Announces Positive Results From Pivotal Trials of Vanzacaftor/Tezacaftor/Deutivacaftor, Next-In-Class Triple Combination Treatment for Cystic Fibrosis | \n'); } if (allow) { document.write('
1/30 - 6:28 AM \; \; | \n'); } if (allow) { document.write('Vertex Announces Positive Results From the VX-548 Phase 3 Program for the Treatment of Moderate-to-Severe Acute Pain | \n'); } if (allow) { document.write('
1/24 - 10:31 AM \; \; | \n'); } if (allow) { document.write('Nasdaq 100 Movers: BKR, NFLX [VIDEO] | \n'); } if (allow) { document.write('
1/17 - 8:00 AM \; \; | \n'); } if (allow) { document.write('Vertex to Announce Fourth Quarter and Full Year 2023 Financial Results on February 5 | \n'); } if (allow) { document.write('
1/16 - 2:24 PM \; \; | \n'); } if (allow) { document.write('Vertex Announces US FDA Approval of CASGEVY™\; (exagamglogene autotemcel) for the Treatment of Transfusion-Dependent Beta Thalassemia | \n'); } if (allow) { document.write('
1/9 - 12:43 PM \; \; | \n'); } if (allow) { document.write('Vertex Announces Approval of First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™\;, for the Treatment of Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT) in Kingdom of Saudi Arabia | \n'); } if (allow) { document.write('
1/7 - 3:00 PM \; \; | \n'); } if (allow) { document.write('Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings | \n'); } if (allow) { document.write('
more news | \n'); } if (allow) { document.write('\n'); } if (allow) { document.write(' |